This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Here Are My ETF Picks For Biotech And Robotics

By John Linnemeier

I’ve found investing in stocks to be a marvelous remedy for hubris, so I’m going to get off of my high-horse about my attitude toward Illumina (ILMN)–which I still think is a marvelous company–and go for a couple of more cautious trades.

In my opinion, the biotech area is finally getting to the stage where big profits are going to be made. The problem is trying to figure out which companies will be making the biggest breakthroughs. I have no way of knowing this for sure, so I’m just going to bet on the sector as a whole.

That’s why I like the iShares Nasdaq Biotechnology ETF (IBB). By the same token, I don’t have any particular insight into the field of robotics, but it doesn’t take a genius to realize that it’s a good field to be in and, again, a field where profits are just starting to take off.

The people responsible for Robo-Stox Global Robotics and Automation ETF (ROBO) are being a little greedy with their 0.65% a year fee. However, until somebody comes up with a more competitive ETF in this area, I’ll grumble a little and pay it.

Just last month, I felt like I was crying in the wilderness about 3D Systems (DDD), and now, at least for the time being, Mr. Market appears to agree with me. I have no way of predicting the future direction of this stock. I do, however, believe in the fundamentals of DDD and in the strategy that management is following.

The investments discussed are held in client accounts as of October 31, 2013. These investments may or may not be currently held in client accounts. The reader should not assume that any investments identified were or will be profitable or that any investment recommendations or investment decisions we make in the future will be profitable. Past performance is no guarantee of future results.
John Linnemeier

John Linnemeier

I'm a writer. The book "How an Average Man Lived an Adventurous Life" is my autobiography. I've spent much of

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.27 -0.76%
FB $101.00 1.47%
GOOG $684.12 0.89%
TSLA $143.67 -3.09%
YHOO $27.10 1.04%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs